Study period 1/1/2021 to 10/1/2024 with follow-up possible through 7/1/2025 Study population: inclusion Patients with: PCOS (encounter or billing diagnosis with ICD-10-CM code E28.2) before exposure or within two years of drug trial start Evaluated sex of female or ambiguous Aged 18 to 50 at drug trial start No overlap in metformin and GLP-1 use At least one measurement within one year prior to trial start At least one measurement 9 to 15 months after trial start At least 70% of days covered by their exposure medication dispense Study population: exclusion Patients with: Evidence of pregnancy during baseline or outcome measurements Definitive pregnancy start date: Between 12 months before the first reading through the follow-up reading Definitive pregnancy end date, delivery, or if its ambiguous what point in the pregnancy the patient would be at (e.g
Often used for body recomposition and metabolic enhancement
We confirmed the effects of these two genes on cellular LD content by overexpressing SREBF1 and PLIN2
According to Raj Singh, MD, FACP, FASN , an internal medicine specialist, nephrologist, and obesity medicine specialist at Healor Health, people taking GLP-1s should expect to stay on them long-term or even indefinitely
H., Korpershoek, E., Lenders, J
One patient developed encephalopathy (brain dysfunction) after a collapse likely caused by cardiac arrhythmia